Next Article in Journal
Cardiac and Cognitive Effects of Androgen Deprivation Therapy: Are They Real?
Previous Article in Journal
Intermittent versus Continuous Androgen Suppression Therapy: Do We Have Consensus Yet?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue s2
10.3747/co.v17i0.723
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Bone Health in Nonmetastatic Prostate Cancer: What’s the Big Deal?

by
J. B. Lattouf
1,* and
F. Saad
2
1
Urologic Oncology Division, Centre Hospitalier de l’Université de Montréal, Montreal, QC H2L 4M1, Canada
2
Departments of Surgery and Urology, Centre Hospitalier de l’Université de Montréal, Montreal, QC H2L 4M1, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(s2), 49-54; https://doi.org/10.3747/co.v17i0.723
Submission received: 4 June 2010 / Revised: 3 July 2010 / Accepted: 7 August 2010 / Published: 1 September 2010

Abstract

Since 2000, the medical community has become increasingly aware of bone health in men with prostate cancer on androgen deprivation therapy (ADT)—mainly because of new therapies that have been shown to reduce bone loss and associated fractures in this patient population. The threat of bone complications has become even more concerning in the prostate-specific antigen era, because ADT is initiated earlier (with biochemical recurrence after local treatment) and maintained longer before the appearance of metastatic disease. The present review examines the relevance of bone health in nonmetastatic prostate cancer, with a discussion of the new treatment modalities available.
Keywords: prostate cancer; androgen deprivation therapy; bisphosphonates; skeletal-related events prostate cancer; androgen deprivation therapy; bisphosphonates; skeletal-related events

Share and Cite

MDPI and ACS Style

Lattouf, J.B.; Saad, F. Bone Health in Nonmetastatic Prostate Cancer: What’s the Big Deal? Curr. Oncol. 2010, 17, 49-54. https://doi.org/10.3747/co.v17i0.723

AMA Style

Lattouf JB, Saad F. Bone Health in Nonmetastatic Prostate Cancer: What’s the Big Deal? Current Oncology. 2010; 17(s2):49-54. https://doi.org/10.3747/co.v17i0.723

Chicago/Turabian Style

Lattouf, J. B., and F. Saad. 2010. "Bone Health in Nonmetastatic Prostate Cancer: What’s the Big Deal?" Current Oncology 17, no. s2: 49-54. https://doi.org/10.3747/co.v17i0.723

APA Style

Lattouf, J. B., & Saad, F. (2010). Bone Health in Nonmetastatic Prostate Cancer: What’s the Big Deal? Current Oncology, 17(s2), 49-54. https://doi.org/10.3747/co.v17i0.723

Article Metrics

Back to TopTop